OncoSynergy has joined forces with the Musella Foundation to raise funds for the company's FDA approved Phase 1 clinical trial in recurrent glioblastoma.

OncoSynergy is a biotechnology company developing innovative therapeutics to improve outcomes for patients suffering from the worst cancers. Glioblastoma has always been at the heart of the company's mission as OncoSynergy was founded by neurosurgeons and scientists frustrated with the lack of effective treatment options and the inability to cure glioblastoma with a scalpel.

OncoSynergy is ready to bring its innovative solution to patients. Our goal is to raise at least $60,000 to fund treatment of at least 1 patient in our FDA approved trial. With your support, we hope to exceed this goal and be able to treat more glioblastoma patients. Each patient we treat helps us and the oncology community better understand how our therapeutic, OS2966, works against cancer. This is powerful information that will allow us to address the shortcomings of today's approach to cancer and translate this cancer treatment to the entire oncology population.

Our mission is led by Co-Founder and CEO, Dr. Anne-Marie Carbonell, a physician trained in neurosurgery. During her neurosurgery training, Dr. Carbonell herself became a patient. No longer able to operate, she has since translated her unique physician/patient dual perspective to OncoSynergy's mission ensuring the company remains patient-focused in its values and clinical trial design.

Key to the trial is OncoSynergy's innovative therapy, OS2966, an anti-CD29 immunotherapy. Current best available cancer therapies target only one biological mechanism that cancer cells use to survive. Unfortunately, history shows that cancer cells adapt by hijacking other biological mechanisms to ensure survival. After decades of lab bench work, OncoSynergy identified a central cancer driver, CD29, as a key gatekeeper between cancer cells and its survival mechanisms. By targeting this "Achilles heel" of cancer, we are able to isolate cancer cells from all lifelines and promote its death.

Please donate by using the form on the right . You can also send a check made out to "Musella Foundation" with "OncoSynergy GBM Trial Fund" in the memo and mail to: 1100 Peninsula Blvd, Hewlett, NY 11557. Call us at 888-295-4740 if you have any problems or questions!

Encourage family and friends to donate! Donations are tax deductible to the full extent of the law.

For more details on this treatment go to: Oncosynergy.com

Oncosynergy GBM Trial Fund Status

Amount Raised:  $1,895.23
Amount Used  $0.00
Current Fund Balance:   $1,895.23

Fund Usage:

No Funds Used Yet!

Donations to the OncoSynergy GBM Trial Fund

If you do donate, please consider checking to see if your employer has a corporate match policy:

  • If donor name differs from that on credit card, enter the donor's name in the comment box!
Donate To:
OncoSynergy GBM Trial Fund
Name on card:
First Name:
Last Name:
State (2 letter abbrev.)
Zip Code
Amount $
Credit Card: American Express
Card Number:
(no spaces, no dashes)
Expiration Month: Month Year
Card Security Code ?
Security Challenge:
We are a 501(c)(3) Nonprofit public charity and
all donations are fully tax deductible in the USA to the full extent of the law.
Our charity ID is: 13-3938057
We DO NOT STORE your credit card number.

If you prefer donating with a check, print out this page and mail it with a check made out to "Musella Foundation" to:
Musella Foundation
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740 Phone
516-295-2870 Fax

The Musella Foundation is a 501(c)(3) Nonprofit Public Charity registered in the USA and donations are tax deductible ONLY in the USA.
Our Federal Tax ID is: 13-3938057

Our privacy / cookie policy has changed.
Click HERE to read it!